Magle Group today announces a strategic direction focused on strengthening profitability, operational discipline, and long-term value creati...
Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as p...
By mutual agreement with the Board of Directors, Justin Pierce has stepped down from his position as Chief Executive Officer, with effect as...
Magle Chemoswed Holding AB announces change of Certified Adviser to Redeye
Magle Group is pleased to announce that it has entered into an exclusive distribution agreement with Rifa Pharma for the Indian market, cove...
As of today, Hans Henrik Lidgard steps down as Chairman of the Board for health reasons and will remain on the Board.
Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S,...
Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Malmö, Sweden – Magle Group announces a revised publication date for its Q3 2025 financial report.
Magle Group is proud to announce its sponsorship of the inaugural Vascular Embolotherapy and Nerve Interventions Targeting Inflammation and ...
Magle Chemoswed Holding AB (publ) (“Magle Group”) today announces that its subsidiary, Magle Biopolymers AB, has received an order for 2026 ...
Magle Group today announces that its review of available clinical evidence for the use of EmboCept® S in Genicular Artery Embolisation (GAE)...
Magle Group today announced that its proprietary surgical innovation, SmartPAN®, has been successfully registered in Singapore.
Magle Group announces its Q2 2025 results amid short-term macroeconomic challenges, highlighting underlying strategic progress despite a tem...
Magle Chemoswed Holding AB (publ) ("Magle Group") today announces that the company’s financial performance in the second quarter of 2025 is ...
Magle Chemoswed Holding AB (publ) ("Magle Group") has today successfully placed senior secured bonds in an amount of SEK 350 million with a ...
Magle Chemoswed Holding AB (publ) (“Magle Group”) has mandated Pareto Securities AB (“Pareto”) to arrange a series of investor meetings comm...
On 24 April 2025, Magle Chemoswed Holding AB ("Magle Group" or the "Company") announced that the Company had signed a share purchase agreeme...
Idag, den 26 maj 2025, hölls årsstämma i Magle Chemoswed Holding AB (publ).
Magle Group's Q1 report highlights a continuation of steady revenue growth in DSM and CDMO, with increased clinical partnerships.
Magle Chemoswed Holding's Annual Report for 2024 has been published on the Group’s website as of today.
Magle Group today announces a further postponement of the publication of its annual accounts for the financial year 2024.
This is a correction of the press release published on 27 March 2025 at 08:30 CET, titled “Magle Chemoswed Holding Reports Financial Results...
Magle PharmaCept, a part of Magle Group, announces a strategic partnership with Pancreatic Cancer Europe (PCE), Pancreatic Cancer Europe is ...
Magle Chemoswed Holding AB ("Magle Group" or the "Company") has today, on 24 April 2025, signed a share purchase agreement regarding the acq...
Aktieägarna i Magle Chemoswed Holding AB (publ), org.
Igår publicerade Magle Group sin Q4-rapport som speglar ökade intäkter, underbyggd av organisk tillväxt och integrationen av två nyckelförvä...
Yesterday, Magle Group released their Q4 report showing a notable increase in revenue, underpinned by organic growth as well as the integrat...
Magle Group's Q4 report highlights strong organic growth in DSM and CDMO, integrates key acquisitions, and expands into dextran-based biopol...
Magle Group has partnered with Heidelberg University Hospital in Germany to launch a study evaluating the effectiveness of SmartPAN in pancr...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has established a collaboration with Heidel...
Ingela Fritzson has today informed Magle Chemoswed Holding AB that she resigns from her position as employee representative in Magle Group’s...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) is pleased to announce Magle PharmaCept’s participation in the DPC, German P...
Malmö, Sweden – Magle Group announces a revised publication date for its Q4 2024 and Full-Year 2024 financial report, and its 2024 Annual Re...
Den 12 december 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") att Bolagets styrelse beslutat, villkorat av...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har idag hållit extra bolagsstämma.
Styrelsen i Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggör idag, den 20 december 2024, utfallet i den företrädesemi...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggör idag tilläggsprospekt (”Tilläggsprospektet”) avseende det prospekt s...
Magle Group is proud to announce that its approved the initiation of a multi-centre clinical trial to explore the use of EmboCept® S in Geni...
Styrelsen i Magle Chemoswed Holding AB (publ) ("Magle Group" eller "Bolaget") har beslutat att genomföra en riktad nyemission av högst 887 3...
Magle Group announces that Petra Jönsson Sjölin has decided to step down from her position as Chief Financial Officer (CFO).
Magle Group is pleased to announce the appointment of Aaron Wong as its new Chief Financial Officer (CFO), effective 7th January 2025.
In the previous press release that was made public on 3 December 2024 it was wrongly stated that Hans Henrik Lidgard is chair of the Nominat...
Malmö, Sweden – Magle Chemoswed Holding (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 20...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") meddelar att prospektet avseende Bolagets företrädesemission av aktier (”Företräd...
Styrelsen i Magle Chemoswed Holding AB (”Magle Group” eller ”Bolaget”) har idag, den 22 november 2024, med stöd av bemyndigandet från årsstä...
Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market exp...
Bolagsverket har idag registrerat fusionen mellan Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") ("Fusione...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggjorde den 28 juni 2024 att Bolaget ingått ett samgåendeavtal med PRS1 A...
Magle Chemoswed Holding AB ("Magle Group") har idag hållit extra bolagsstämma.
Styrelsen för Magle Chemoswed Holding AB ("Magle Group") har idag, med stöd av bemyndigandet från årsstämman den 25 april 2024, beslutat att...
In an ambitious move to transform wound care, Magle Chemoswed and I2Pure have unveiled a joint venture, marrying I2Pure's groundbreaking mol...
Bolagsverket har idag lämnat tillstånd till Magle Chemoswed Holding AB ("Magle Group") att verkställa fusionsplanen avseende fusionen mellan...
The company aims to establish itself as a leader in life-changing healthcare innovations.
BioStock intervjuar Magle Group om bolagets rapport för det första halvåret 2024 och dyker in bland annat in i bolagets tillväxt, den ökade ...
Magle Group's Q2 report highlights organic sales growth and future market expansion with startegic mergers
Idag meddelar Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") att fusionsdokumentet avseende fusionen ("Fusionen") med Amniotics ...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har idag tillträtt aktierna i förvärvet av pK Biotech ApS ("pK Biotech") och dess...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har ingått ett samgåendeavtal med PRS1 ApS (”Säljaren”) avseende förvärv av samtl...
Flexibiliteten hos ett mindre företag och bredden hos de största bolagen – så beskriver Magle Group sitt erbjudande.
Magle Group fokuserar på fortsatt tillväxt genom breddning av CDMO-erbjudandet och utveckling av fler medicinska produkter baserade på Degra...
Magle Chemoswed Holding AB ("Magle Group") har ingått ett bindande avtal att förvärva samtliga aktier i pK Biotech ApS och dess dotterbolag ...
Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") (tillsammans "Bolagen") meddelar idag, den 30 maj 2024, att...
Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle" eller "Magle Group") (STO: MAGLE), ett ledande CDMO-företag (Contract D...
Idag, den 25 april 2024, hölls årsstämma i Magle Chemoswed Holding AB (publ).
Today, on 18 April 2024, Magle Chemoswed Holding AB (publ) has published its interim report for Q1, 2024.
Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle Group") ett rekommenderat offentligt uppköpserbjudande till aktieägarna ...
Magle Chemoswed Holding's Annual Report for 2023 has been published on the Group’s website as of today.
The Board of Directors' of Magle Chemoswed Holding AB (publ) (“Magle Group” or the “Company”) assessment of the Company's dividend capacity ...
Magle Chemoswed Holding AB[1] ("Magle" eller "Magle Group") offentliggör härmed ett rekommenderat offentligt uppköpserbjudande till aktieäga...
Magle Chemoswed Holding AB (publ), an established innovation-led healthcare group with proven growth through risk diversification and focus ...
Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the establishment of a collaboration and exclusive worldwide...
Today, on 18 Julyl 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q2 2023.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has filed a new patent application for its ...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company’s CEO Justin Pierace purhases 172,800 Magle...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the presentation of data from the company’s first post-marke...
Idag, den 26 april 2023, hölls årsstämma i Magle Chemoswed Holding AB (publ).
Today, on 19 April 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q1 2023.
Magle Chemoswed Holding's Annual Report for 2022 has been published on the Group’s website as of today.
Aktieägarna i Magle Chemoswed Holding AB (publ), org nr.
Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus ...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that AXXO® Woundgel has received regulatory approval in Kuwa...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that Embocept® S has received regulatory approval in Argenti...
Today, on 9 November 2022, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2022.
Magle Chemoswed Holding AB (publ) will publish its interim report for Q3 2022 on Wednesday 9 November 2022 at 08:30 CET.
Magle Chemoswed Holding AB (publ) hereby announces that the company has entered into an agreement with Vator Securities AB (“Vator Securitie...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the appointment of Helena Ossmer Thedius as Chief Marketing ...
Magle Chemoswed Holding Reports Financial Results For First Half year 2022
Julia Kamber Rouhi, a deputy member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Bo...
Magle Chemoswed Holding AB (publ) will publish its interim report for Q2 2022 on Wednesday 17 August 2022 at 08:30 CET.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the first patients have been included in a post-market ...
The Magle Group’s sponsorship of the SmiLe incubator is part of the Group’s commitment to supporting early-stage companies develop and comme...
Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 17 Maj 2022
The Magle Group today announces that it will commence its post market clinical study in collaboration with the University of Heidelberg, Med...
